U

Unilabs

Offers medical diagnostics and imaging services

Iberia Technology Lead

Full-TimePosted on 10/21/2026
No salary listed
Expert
Porto, Portugal
HybridHybrid; approximately 3 days per week in the Porto office.
Engineering ManagementEngineering Leadership

About the job

Requirements
  • Significant leadership experience across technology, architecture, engineering, or infrastructure functions.
  • Experience managing managers and multidisciplinary technology teams.
  • Proven leadership in technology transformation programmes.
  • Strong understanding of architecture, software engineering, infrastructure, and cloud environments.
  • Experience governing complex technology portfolios and strategic roadmaps.
  • Experience in supplier and vendor management.
  • Strong stakeholder-management experience within matrix organisations.
  • Experience balancing operational excellence with transformation and innovation.
  • Fluency in English and Portuguese.
  • Strategic thinking with a strong execution focus.
  • Ability to bring structure and clarity to complex environments.
  • Strong people leadership and coaching capability.
  • Effective decision-making under ambiguity.
  • Excellent stakeholder and relationship management.
  • Ability to influence across organisational boundaries.
  • Commercial awareness and technology investment discipline.
  • Strong ownership, accountability, and customer orientation.
Responsibilities
  • Act as the primary technical advisor to the Head of IT Iberia.
  • Define and maintain the Iberia technology strategy and multi-year technology roadmap within the Group technology strategy, target architecture, and standards.
  • Translate Group technology direction, architectural principles, and standards into Iberia implementation priorities, identifying local requirements, constraints, and justified exceptions.
  • Work in close functional partnership with the Global Head of Technology Design and relevant Group technology leaders, ensuring early alignment on strategic technology and architecture decisions.
  • Represent Iberia requirements and priorities in Group technology strategy, architecture, and standards, and contribute to their continued evolution.
  • Establish local technology governance, decision-making frameworks, and accountability across Architecture, Interoperability, and Infrastructure domains, consistent with Group governance and decision rights.
  • Ensure technology strategies, standards, and roadmaps address the operational, regulatory, and business requirements of Portugal and Spain while maintaining alignment with Group direction, and ensure exceptions are reviewed through appropriate Group architecture and technology governance forums.
  • Partner with Product and Service Management leaders to translate business priorities into sequenced technology roadmaps, ensuring clear accountability between product direction, technical delivery, and operational service ownership.
  • Resolve cross-domain priorities, architectural conflicts, dependencies, and capacity constraints across Architecture, Interoperability, and Infrastructure.
  • Lead strategic technology planning and provide recommendations regarding investment priorities, technology evolution, and risk trade-offs.
  • Drive the evolution of the Iberia technology operating model.
  • Lead, coach, and develop the managers responsible for Architecture, Interoperability, and Infrastructure.
  • Foster a culture of accountability, ownership, delegation, and continuous improvement.
  • Establish clear objectives, performance expectations, and development plans.
  • Build succession capability within all technical domains.
  • Support hiring, retention, and leadership development of key technical talent.
  • Strengthen collaboration between technology teams and business stakeholders.
  • Lead the implementation and evolution of the Iberia technology architecture in alignment with Group target architecture, technology principles, and standards.
  • Drive the evolution of core platforms towards more modular, scalable, and maintainable architectures.
  • Guide major architecture decisions across development and platform initiatives, ensuring alignment with Global Technology Design and appropriate Group architecture governance.
  • Adopt and operationalise Group engineering and technology standards or, where unavailable, establish engineering standards covering quality, testing, observability, security, and continuous integration/continuous delivery in alignment with the Global Head of Technology Design.
  • Reduce technical debt and architectural complexity while maintaining delivery momentum.
  • Promote modern software engineering practices and continuous improvement.
  • Ensure consistent governance over platform design, system integration, and technology standards.
  • Define and govern enterprise integration principles and standards.
  • Ensure interoperability solutions are scalable, secure, and aligned with business objectives.
  • Promote application programming interface-first and loosely coupled integration approaches.
  • Oversee integration risk, dependency management, and platform interoperability.
  • Ensure licensed and internally developed solutions integrate effectively within the broader technology landscape.
  • Guide strategic decisions regarding healthcare interoperability standards, integration platforms, and integration governance.
  • Provide executive oversight of infrastructure, cloud, platform, and operational technology services.
  • Ensure infrastructure strategies support current and future business needs.
  • Oversee service reliability, availability, lifecycle management, and resilience.
  • Govern major infrastructure investment decisions and technology refresh plans.
  • Ensure cloud adoption, platform modernisation, and infrastructure transformation align with the overall technology strategy.
  • Maintain oversight of cybersecurity remediation priorities, infrastructure risks, and operational resilience measures.
  • Ensure business continuity, disaster recovery, and resilience capabilities remain effective and regularly validated.
  • Establish clear service transition requirements for all technology initiatives.
  • Ensure operational readiness, support ownership, and documentation requirements are met before production deployment.
  • Drive structured problem management and resolution of recurring technology issues.
  • Ensure technology risks are identified, reported, and actively managed.
  • Provide executive governance for strategic technology suppliers and service providers.
  • Oversee supplier performance, contractual obligations, risks, service levels, and improvement plans.
  • Support sourcing decisions, build-versus-buy assessments, and technology procurement initiatives.
  • Manage relationships with key technology partners and vendors.
  • Ensure supplier strategies align with Iberia technology objectives.
  • Own the consolidated Iberia technology investment roadmap.
  • Lead budget planning and technology investment prioritisation across technical domains.
  • Develop business cases supporting transformation and modernisation initiatives.
  • Balance business value, technical risk, operational impact, and cost considerations.
  • Provide technology portfolio reporting and investment recommendations to senior leadership.
  • Maintain oversight of technology, infrastructure, and integration risks and architectural debt.
  • Ensure alignment with cybersecurity policies, governance controls, and regulatory requirements.
  • Support compliance with the General Data Protection Regulation, healthcare regulations, and Group standards.
  • Ensure key technology decisions are documented through appropriate governance forums.
  • Create visibility through key performance indicators, dashboards, and executive reporting.
Desired Qualifications
  • Healthcare, diagnostics, life sciences, or regulated-industry experience.
  • Experience modernising legacy platforms and technology estates.
  • Knowledge of interoperability standards such as Health Level Seven and Fast Healthcare Interoperability Resources.
  • Domain-driven design, event-driven architectures, and modern integration patterns.
  • Cloud transformation experience in Azure and hybrid environments.
  • Awareness of the Network and Information Security Directive 2, cybersecurity frameworks, and artificial-intelligence-assisted development practices.

About the company

U

Unilabs

View
Website

Unilabs is an international diagnostics provider that delivers medical testing and imaging services for healthcare providers, hospitals, and patients across Europe. Its offering covers laboratory testing, radiology imaging, and pathology analyses, with results used to guide treatment decisions. The company operates by collecting patient samples, running standardized tests in its labs, performing imaging studies, and delivering clear diagnostic reports to clinicians, all under strict quality control to ensure accuracy. What sets Unilabs apart is its extensive geographic reach, long history in diagnostics, and a strong emphasis on quality and continuous improvement, enabling integrated, reliable services across multiple countries. The company’s goal is to deliver precise, timely diagnostic information to support effective patient care and treatment decisions.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Coppet, Switzerland

Founded

1987

Get referred to Unilabs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 digital pathology expansion standardizes workflows and speeds second opinions.
  • WHOOP launched UAE Advanced Labs on 12 February 2026, adding recurring biomarker volume.
  • Pangea's November 2024 bladder assay and C2N blood tests widen specialty-test revenue.

What critics are saying

  • Unilabs Limited entered administration on 31 July 2026; UK operations were distressed-sold.
  • Portugal class action filed 2 March 2026 targets Unilabs for alleged collusion.
  • PureHealth's Circle now controls selected UK labs, stripping Unilabs of a key market.

What makes Unilabs unique

  • September 2026 Proscia rollout gives Unilabs network-wide digital pathology scale.
  • WHOOP and Bioniq partnerships embed Unilabs testing into consumer health platforms.
  • Forty-plus countries and 13,000 employees create cross-border diagnostic breadth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

23%

2 year growth

23%
Samedan Ltd
Sep 15th, 2026
Circle Health Group expands into UK laboratory operations.

Circle Health Group expands into UK laboratory operations. Circle Health Group (Circle) has expanded into laboratory operations across the UK through the acquisition of selected laboratory operations from Unilabs. The operations, which have transferred to Circle, provide pathology, histopathology, blood sciences, microbiology and specialist diagnostic services to more than 90 external healthcare clients. The move will allow Circle to integrate laboratory services more closely with its hospital network, with the group aiming to improve collaboration between clinicians and laboratory specialists while increasing operational capacity and responsiveness. Circle Health Group is part of global healthcare group PureHealth and will draw on the expertise of its laboratory subsidiary, PureLab. The company operates more than 150 laboratories and processes more than 25 million tests annually, with capabilities including automation and AI-enabled diagnostics. Paul Manning, CEO of Circle Health Group, said integrating diagnostics with its hospitals would create a more connected model of care. "Integrating diagnostics more closely with our hospitals allows us to deliver a more connected model of care," he said. "It strengthens collaboration between clinicians and laboratory specialists, improves operational responsiveness and provides a strong foundation to support our continued growth." Circle said the laboratory network would continue to prioritise its existing external healthcare clients, while also providing capacity for new customers. The group said the expansion formed part of its multi-year growth strategy, with investment planned in laboratory equipment, technology and scientific and clinical staff. The acquisition will also enable Circle to expand diagnostic services across its hospital network, with the company aiming to improve access to testing and reduce turnaround times. No items found

Business Wire
Feb 12th, 2026
WHOOP partners with Unilabs to launch Advanced Labs in UAE with 65-biomarker panel

WHOOP has partnered with Unilabs to launch Advanced Labs in the UAE, enabling members to integrate clinical blood biomarker data with their continuous health tracking. The partnership allows WHOOP members to book a 65-biomarker panel through Unilabs for 733 AED, with testing available at Unilabs centres or via home collection. Members can upload lab results directly to the WHOOP app, where they receive personalised guidance from WHOOP Coach that contextualises biomarkers alongside recovery, sleep and daily behaviours. The integration provides long-term health trend analysis in one platform. Founded in 2012, WHOOP has raised over $400 million and ships to 56 markets worldwide. Unilabs is an international diagnostic services provider operating across four continents, serving nearly 100 million people annually.

Zawya
Dec 18th, 2025
Unilabs Middle East and EMANT Society launch kidney health awareness and screening campaign

Unilabs Middle East and EMANT society launch kidney health awareness and screening campaign. Campaign to kick off in collaboration with Emirates Health Services (EHS) and the National Programme for Organ and Tissue Donation and Transplantation, "Hayat" * Running for five months, the drive aims to reach 10,000 participants across the UAE Unilabs Middle East, a leading diagnostic service provider, has joined forces with the the Emirates Medical Association, Nephrology and Transplantation Society (EMANT) to launch the Kidney Health Awareness and Screening Campaign. The campaign aims to raise awareness about the importance of kidney health and encourage early detection by offering free screening services throughout the campaign period. It comes as part of community initiatives and in line with the UAE's national policy to promote healthy lifestyles. In collaboration with Emirates Health Services (EHS) and "Hayat," the National Programme for Organ and Tissue Donation and Transplantation, the campaign will run for five months, reaching more than 10,000 people across the UAE. Additional partners from both government and private sectors are expected to come on board to expand the campaign's reach and impact. The campaign is proudly supported by leading pharmaceutical companies, including Boehringer Ingelheim, Novartis, Vantive, and CSL., whose commitment to advancing community health and preventive care continues to drive meaningful impact across the UAE. It is set to make a wide-reaching impact by promoting preventive healthcare and supporting national health priorities in the UAE. Key activities include open days for basic laboratory testing at multiple locations, alongside educational workshops, school exhibitions, and interactive community events designed to engage diverse audiences and raise awareness across all age groups. Dr. Shaikha Rashid Obaid Ali, Consultant Internal Medicine & Nephrology, Sheikh Khalifa Medical City Ajman, and Scientific Committee Chairperson, Emirates Medical Association Nephrology and Transplantation Society (EMANT), said: "The Kidney Health Awareness and Screening Campaign represents an important milestone in our ongoing mission to promote kidney health across the UAE. By focusing on prevention, early detection, and community education, we aim to reduce the rising burden of chronic kidney disease and encourage individuals to take proactive steps in safeguarding their health. At EMANT, our vision is to advance kidney health through awareness, research, and collaboration, ensuring that every member of our community has access to the knowledge and support needed for early intervention and better outcomes." The initiative aims to empower individuals to take charge of their health through early detection and to provide free screening services for those most at risk. EMANT official urged members of the public to participate in the campaign, fostering a healthier and more informed society. Dr. Ali Bayoumi, Medical Director SBU Genetics Unilabs Global, and Medical Director Middle East Cluster Said: "Our partnership with EMANT falls under the umbrella of our Year of Community initiatives and reflects our shared belief that preventive healthcare and early diagnosis are key pillars of building a healthier society. We are proud to contribute to this vital campaign that will benefit thousands across the UAE." He added, "Unilabs is committed to playing a key role as a trusted diagnostics partner, leveraging its extensive expertise and advanced laboratory capabilities to deliver accurate and timely results. This would support early detection and help take the right health decisions, in line with the national policy to promote healthy lifestyles." Unilabs and the Emirates Medical Association, Nephrology and Transplantation Society call on all members of the community, particularly those with chronic health conditions, to participate in the campaign's free events and screenings. They also urge healthcare professionals to help amplify the message by raising awareness within their clinics and facilities as part of a collective effort to achieve the campaign's goal of screening 10,000 participants. About Unilabs Unilabs is a leading global provider of diagnostic services, offering a comprehensive package of laboratory, pathology, and genetic solutions across four continents. With more than 13,000 specialists in 14 countries, Unilabs leverages cutting-edge digital technologies in its laboratories to enhance the lives of nearly 100 million people each year. Boasting over 30 years of experience in pharmaceutical solutions, Unilabs specialises in clinical trials conducted within environments regulated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Unilabs: For more information, please contact [email protected] Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an "as is" and "as available" basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk. To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

CoinCentral
Aug 8th, 2025
Unilabs Raises $11.9M, Offers 30% ROI

Unilabs, a DeFi platform, raised $11.9M and offers a 30% staking ROI, attracting over 10,000 investors. It provides AI-driven tools for smarter trading and revenue sharing with UNIL holders. Unilabs aims to simplify DeFi with features like cross-chain trading and flash loans. Analysts predict UNIL could reach $1 soon, with potential to outperform XRP. A 50% bonus is available for early buyers using code CMC50.

Kearney
Jun 12th, 2025
Investing in Europe's next chapter: navigating geoeconomic shifts and building regional champions

A.P. Moller Holding's acquisition of Unilabs, one of Europe's largest diagnostics services provider and digital champion, from Apax Partners diversified its portfolio and created the opportunity to scale through marrying healthcare tech with existing expertise in automation and logistics.